Account
Publications
03.12.2021
Highly specialised technologies process

Is the National Institute for Health and Care Excellence (NICE) becoming more efficient in evaluatin...

Read more
Publications
03.12.2021
Orphan drug status benefit

The purpose of this study is to compare the assessments of orphan and non-orphan drugs by NICE.

Read more
Publications
19.11.2020
ISPO 2020 Developing a sustainable biosimilar

To facilitate biosimilar uptake, several mechanisms aimed at reducing the acquisition cost of biosim...

Read more
Publications
19.11.2020
COVID-19 impact on HTA bodies

HTA bodies and companies within the pharmaceutical industry have been forced to react to unprecedent...

Read more
Publications
19.11.2020
ISPOR 2020 New NICE STA process

This study aimed to assess whether the new process has resulted in changes to outcomes of STAs.

Read more
Publications
19.11.2020
NICE increased speed of patient access

This study aimed to review timelines and use of financial agreements for products being appraised.

Read more
Publications
06.11.2019
Secure patient access

This study investigates how gaps in the current evidence are linked to access restrictions and mitig...

Read more
Publications
06.11.2019
A comparison of oncology and non-oncology appraisa

In this study, we compared the use of financial agreements for oncology and non-oncology drugs asses...

Read more
Publications
06.11.2019
Top 20 most expensive drugs in US

Top 20 most expensive drugs in the US.

Read more
Publications
06.11.2019
Pricing and market access launch excellence

Pharmaceutical companies are incorporating payer / HTA needs into their clinical and commercial laun...

Read more

Stay in the know, subscribe to our newsletter

Be the first to receive exclusive content on the latest from the pharmaceutical and market access sector.